Sanofi India Ltd
NSE:SANOFI
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6 054.05
10 072.65
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Sanofi India Ltd
Sanofi India Ltd
Net Income
Sanofi India Ltd
Net Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sanofi India Ltd
NSE:SANOFI
|
Net Income
₹6B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Net Income
₹72.3B
|
CAGR 3-Years
35%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Net Income
₹63.3B
|
CAGR 3-Years
20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Net Income
₹128.4B
|
CAGR 3-Years
22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Net Income
₹25.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Net Income
₹24B
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sanofi India Ltd
Glance View
Sanofi India Ltd., a prominent name in the pharmaceutical landscape, operates as a subsidiary of Sanofi S.A., the global healthcare giant headquartered in France. Its roots in India trace back to the early 1950s when it began importing and distributing vaccines. Over the decades, Sanofi India has evolved into a comprehensive provider of high-quality drugs, contributing significantly to the nation’s healthcare ecosystem. The company focuses primarily on therapeutic segments such as diabetes, cardiovascular diseases, oncology, and vaccines, boasting a robust portfolio of prescription medicines and over-the-counter products. By leveraging a vast network of healthcare professionals and engaging in continuous clinical research and development, Sanofi India ensures its position at the forefront of medical innovation, adhering to a global strategy of patient-oriented solutions and a commitment to improving health outcomes. Sanofi India's revenue model revolves around its diversified product portfolio, addressing a spectrum of critical health areas. The company generates income through the sale of its flagship products, which include insulin for diabetes management, anti-allergy medications, and innovative therapies for rare diseases, among others. While the domestic market plays a crucial role in its financial framework, Sanofi India also taps into international markets, exporting its high-quality pharmaceutical products across borders. The profitability of the company is further bolstered by its commitment to research and development, enabling it to introduce new drugs and therapies, thus continually expanding its market share. By maintaining strong distribution channels and fostering collaborations with medical institutions and regulatory bodies, Sanofi India ensures its products reach a broad consumer base, perpetuating its growth trajectory in the competitive pharmaceutical scene.
See Also
What is Sanofi India Ltd's Net Income?
Net Income
6B
INR
Based on the financial report for Sep 30, 2024, Sanofi India Ltd's Net Income amounts to 6B INR.
What is Sanofi India Ltd's Net Income growth rate?
Net Income CAGR 3Y
-9%
Over the last year, the Net Income growth was -27%. The average annual Net Income growth rates for Sanofi India Ltd have been -9% over the past three years .
You don't have any saved screeners yet
